Work safety has only a starting point, no end
Release time:
2020-08-14
safety production work has only a starting point and no end point
"a lesson from the past and a teacher from the future". safety work has only a starting point and no end point. it can only be strengthened and cannot be relaxed at any time. If every employee in the cement industry does not have the safety production awareness of "safety first, prevention first", then not only will there be no possibility of "safety, stability, length, fullness, and excellence", but also to oneself and family., The performance of irresponsibility to colleagues.
Safety and good production order are the most concentrated manifestation of the company's guarantee of safe development and the continuous improvement of employees' living standards. This is also the most basic requirement for our company's safe production. Failure to listen to the advice of safety first is the naivety of the ears; people who do not know how to take precautions and whose responsibilities are more important than Mount Tai are the naivety of the soul; not going deep into the front line, eliminating all kinds of potential safety hazards, and giving safety to others is the naivety of behavior.
In the safety dust collection accidents, the vast majority of the company's main leaders and employees are lucky and the safety measures are not in place. Indeed, in the safety production practice of enterprises, it is some people who have such thoughts that lead to accidents, ranging from equipment damage or property loss to casualties. If each major person in charge or person in charge of safety can establish the idea that "safety work has only a starting point, no end point, and can only be strengthened and not relaxed at any time", 100% strictly follows the system and safety operation procedures, safety accidents are impossible. Check in place, do not miss a detail; measures in place, do not miss a doubt, many accidents can be avoided.
For example, we have only implemented 8 of the 10 safety measures for a project, so we cannot say that the project has passed the safety work. Often, the remaining two measures may be the hidden danger of safety accidents and the main cause of accidents. The safety of the past cannot represent the safety of the present and the future. For us, a small mistake or a small negligence can lead to accidents. Only by tightening the string of safety at all times can we ensure the safety of the company, ensure our own safety, and ensure the happiness and happiness of every employee's family. (Liu Fengbin)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31